Business Context and Reporting Period
Company: Indivior Pharmaceuticals, Inc. (Successor to Indivior PLC)
Filing Type: Form 10-K Annual Report
Reporting Period: Fiscal year ended December 31, 2025
Corporate Status: The Company completed a U.S. Domestication on January 23, 2026, changing its domicile from the U.K. to Delaware. The financial statements presented are those of Indivior PLC, which will become the historical statements of the new U.S. parent company.
Indivior is the market leader in long-acting injectable (LAI) medications for opioid use disorder (OUD). Its core products are SUBLOCADE (LAI) and SUBOXONE Film (sublingual). The U.S. market accounts for approximately 85% of net revenues.
Key Financial Metrics
| Metric (in millions) | 2025 | 2024 | % Change |
|---|---|---|---|
| Net Revenue | $1,239 | $1,188 | 4% |
| Gross Profit | $994 | $957 | 4% |
| Gross Margin | 80% | 81% | -1% |
| Operating Income | $262 | $38 | 594% |
| Net Income | $210 | $7 | NM |
| Diluted EPS | $1.64 | $0.05 | NM |
| Cash and Cash Equivalents | $195 | $319 | -39% |
| Total Debt (Outstanding) | $333 | $350 | -5% |
| Accrued Rebates & Returns | $582 | $562 | 4% |
Note: "NM" indicates Not Meaningful due to low prior period base.
Material Changes vs. Prior Period
- Profitability Surge: Operating income increased 594% to $262 million, driven primarily by a $192 million decrease in litigation settlement expenses (from $195 million in 2024 to $3 million in 2025) and improved operating leverage.
- Revenue Growth: Net revenue grew 4% to $1,239 million. SUBLOCADE revenue increased 13% to $856 million, offsetting declines in sublingual products (down 7%) and discontinued products (OPVEE and PERSERIS).
- Restructuring Costs: The Company incurred $127 million in restructuring and exit costs in 2025 related to the "Indivior Action Agenda," including headcount reductions, facility closures, and the discontinuation of OPVEE sales support.
- Cash Flow: Net cash used in operating activities was $27 million in 2025, compared to $36 million provided in 2024. This shift was largely due to $208 million in litigation settlement payments in 2025, including a prepayment of the remaining DOJ liability.
- Financial Restatement: The Company revised previously issued financial statements for 2023 and 2024 to correct an overstatement of the U.S. Branded Fee accrual, resulting in a $5 million increase to 2024 net income.
Guidance, Outlook, and Risks
Outlook and Management Commentary
- 2026 Revenue Expectation: Management expects total net revenue to decline in 2026 compared to 2025. This is due to the exit from several non-U.S. markets (U.K., Ireland, Sweden, Israel, Finland, Italy) and continued competitive pressure on SUBOXONE Film.
- Cost Reduction: Total operating expenses are expected to decrease substantially in 2026 as restructuring savings are realized and R&D expenses are refocused on two key pipeline assets (INDV-6001 and INDV-2000).
- Capital Expenditures: Expected to be $30 million to $40 million in 2026, primarily for the Raleigh Manufacturing Facility.
Key Risks and Contingencies
- Liquidity and Leverage: The Company has negative working capital (current liabilities exceed current assets by over $250 million) due to the timing of rebate payments. Total liabilities exceed total assets by approximately $100 million. The Company relies on cash flow from operations to meet obligations.
- Debt Covenants: The Note Purchase Agreement includes financial covenants (Total Leverage Ratio < 3.0:1 through Sept 2026; Interest Coverage Ratio > 2.5:1). The Company was in compliance as of December 31, 2025.
- Legal Proceedings:
- Opioid MDL: A settlement framework with states and subdivisions was finalized in 2025, with an accrued liability of $80 million. Private plaintiff cases remain unresolved.
- Dental Allegations: Approximately 2,000 cases consolidated in MDL alleging dental injury from SUBOXONE Film. No estimate of loss can be made at this time.
- DOJ Resolution: The Company completed all obligations under the 2020 Resolution Agreement in November 2025.
- Product Concentration: SUBLOCADE accounted for 69% of net revenue in 2025. The Company relies heavily on this single product for growth.
Investor Verification Checklist
- Liquidity Position: Verify the Company's ability to service debt and meet working capital needs given the negative working capital position and reliance on operating cash flow.
- Rebate Accruals: Review the $582 million accrued rebate liability, identified as a critical audit matter, and the sensitivity of estimates to payer mix changes.
- 2026 Revenue Decline: Assess the impact of exiting non-U.S. markets and the erosion of SUBOXONE Film market share on future top-line growth.
- Legal Exposure: Monitor the status of unresolved private plaintiff cases in the Opioid MDL and the Dental MDL, as these could result in significant future charges.
- Restructuring Execution: Confirm that the anticipated cost savings from the "Indivior Action Agenda" are realized in 2026 to offset revenue declines.